What is the origin of ulcerative colitis? Still more questions than answers

Postgraduate Medical Journal

Volumn 82, Issue 972, 2006, Pages 620-625

  Lukas, Milan ^a   Bortlik, Martin ^a   Maratka, Zdenek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; ORAL CONTRACEPTIVE AGENT; TUMOR NECROSIS FACTOR;

APPENDECTOMY; CROHN DISEASE; DIET; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; INCIDENCE; INTESTINE FLORA; MENTAL DISEASE; MUCOSAL IMMUNITY; ORAL CONTRACEPTION; PATHOGENESIS; REVIEW; SMOKING; STRESS; ULCERATIVE COLITIS;

APPENDICITIS; BACTERIAL INFECTIONS; COLITIS, ULCERATIVE; CONTRACEPTIVES, ORAL; DIET; EPITHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SMOKING; STRESS, PSYCHOLOGICAL;

EID: 33751200666     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.2006.047035     Document Type: Review

References (61)

1. Cantor M, Bernstein ChN. Clinical course and natural history of ulcerative colitis. In: Sartor RB, Sandborn WJ, eds. Kirsners inflammatory bowel disease. Toronto: Elsevier, 2004:280-8.
2. Lakatos L, Lakatos LP. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? World J Gastroenterol 2006;82:332-7.
3. Wilks S. The morbid appearance of the intestine of Miss Banks. Med Times Gazette 1859;2:264.
4. Kirsner JB. Inflammatory bowel disease at The University of Chicago - early experience: a personal Historical account. Inflamm Bowel Dis 2005;11:407-16.
5. Guarner F. Microecology as a target for therapeutic intervention in inflammatory bowel disease. Drugs 2003;6:868-73.
6. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2003;124(Suppl 1):S1370.
7. Marteau P, Lepage P, Mangin I, et al. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(Suppl 4):S18-23.
8. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implication. In: Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel diseases. Toronto: Elsevier, 2004:138-62.
9. Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002;37:1034-41.
10. Macfarlane S, Furrie E, Cummings JH, et al. Chemotoxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 2004;38:1690-9.
11. Tamboli CP, Neut C, Desreumax P, et al. Dysbiosis in inflammatory bowel disease. Gut 2004;53:1-4.
12. Furrie E, Macfarlane S, Cummings JH, et al. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut 2004;53:91-8.
13. Okhusa T, Sato N, Ogiharo T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastro-Hepatol 2002;17:849-53.
14. Mow WS, Vasiliauskas EA, Lin YV, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohns disease. Gastroenterology 2004;126:414-24.
15. Van de Merwe JP, Schroder AM, Wensinck F, et al. The obligate anaerobic fecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988;23:1125-231.
16. Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001;17:324-30.
17. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 2005;21:414-18.
18. Borruel N, Carol M, Casellas F, et al. Increased mucosal production TNF-α in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
19. Mudter J, Neurath M. Mucosal T cells: mediators or guardians of inflammatory bowel disease? Curr Opin Gastroenterol 2003;19:343-9.
20. Rogler R. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004;20:311-17.
21. Rook G, Brunet LR. Microbes, immunoregulation and the gut. Gut 2005;54:317-20.
22. Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut 2005;54:900-3.
23. Ismail AS, Hooper LV. Epithelial cells and their neighbors. IV. Bacterial contributions to intestinal epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol 2005;289:G779-84.
24. Mumy KL, McCormick BA. Events at the host-microbial interference of the gastrointestinal tract II. Role of the intestinal epithelium in pathogen-induced inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G854-9.
25. Stange EF. Defensins in pathogenesis of IBD. Proceedings of the Annual IOIBD meeting. Bokabung, South Africa, 2006.
26. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5-36.
27. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759-66.
28. Schwab M, Schaffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33.
29. Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissues Antigens 2003;62:527-35.
30. Vermeire S, Rutgeerts P, Van Steen K, et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistatis. Gut 2004;53:980-6.
31. Borm MEA, Van Bodegraven AA, Mulder CJJ, et al. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005;32:401-5.
32. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptors (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53:987-92.
33. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000;47:861-9.
34. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79-84.
35. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroentrol 2003;98:2203-8.
36. 3o Mawdsley JE, Rampton DS. Psychological stress in IBD. New insights into pathogenic and therapeutic manipulations. Gut 2005;54:1481-91.
37. Jantechek G, Zeitz M, Pritsch M, et al. Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand J Gastroenterol 1998;33:1289-96.
38. Boyko EJ, Perera DR, Koespell TD, et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988;23:1147-52.
39. Ingram JR, Rhodes J, Ewans BK, et al. Preliminary observations of oral nicotine therapy for inflammatory bowel disease. An open-label phase I-II study tolerance. Inflamm Bowel Dis 2005;11:1092-6.
40. Sandborn WJ, Tremaine W, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized double-blind, placebo controlled trial. Ann Intern Med 1997;126:364-71.
41. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptives agents in inflammatory bowel disease. Gut 1995;37:668-73.
42. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999;94:427-33.
43. Tilg H, Kaser A. Diet and relapsing ulcerative colitis: take off the meat? Gut 2004;43:1399-401.
44. Russel MG, Engels LG, Muris JW, et al. Modern life in the epidemiology of inflammatory bowel disease: a case control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998;10:243-9.
45. Koutroubakis I. E, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a meta-analysis of published case-control studies, Am J Gastroenterol 2000;95:171-6.
46. Sandler RS, Loftus EV Jr. Epidemiology of inflammatory bowel diseases. In: Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel disease. Toronto: Saunders, 2004:245-62.
47. Maratka Z, Wagner V. The treatment of non-specific ulcerative colitis by autogenous vaccine. Correlated bacteriological and immunological studies. Gastroenterology 1948;11:34-49.
48. Maratka Z, Spellberg MA. Observations on the clinical course of nonspecific ulcerative colitis. Gastroenterology 1949;12:79-86.
49. Maratka Z, Nedbal J, Kocianova J, et al. Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years. Gut 1985;26:43-9.
50. Havelka J, Kocianova J, Maratka Z, et al. Statistical analysis of 303 cases of regional enteritis [in Czech, with English summary]. Cs Gastroent Vyz 1993;47:3-9.
51. Maratka Z. Colitis ulcerosa. Praha: Unie, 1948.
52. Maratka Z. Pathogenesis and aetiology of inflammatory bowel disease. In: DeDombal FT, Myren J, Bouchier IAD, Watkinson G, eds. Inflammatory bowel disease. Oxford: Oxford University Press, 1986 (1st edn), 1993 (2nd edn).
53. Maratka Z. The role of intestinal bacteria in the pathogenesis of inflammatory bowel diseases. A two-component hypothesis. Folia Gastroenterol Hepatol 2003;1:6-11.
54. Maratka Z, Wagner V. Recherches sur les autoanticorps anticolon au cours de la rectocolite hemorrhagique. Rev Franc Etud Clin Biol 1961;6:182-5.
55. Maratka Z, Wagner V. On the role of the autoimmune mechanism in the genesis of ulcerative colitis. Acta Allerg 1963;18:100-9.
56. Maratka Z. Differential diagnosis of inflammatory bowel diseases and the problem of so called indeterminate colitis [in Czech, with English summary]. Czech Slovak Gastroenterol Hepatol 2003;57:8-17.
57. Weinstock JV, Summers R, Elliot DE. Helminths and harmony. Gut 2004;53:7-9.
58. Rook GAW, Brunet LR. Chronic inflammatory disorders, the gut and "Old Friends" hypothesis. In: Colombel JF, Gashe C, Scholmerich J, Vucelic B, eds. Inflammatory bowel disease: translation from basic research to clinical practice. Folk Symposium. Vol 140. Berlin: Springer, 2005:43-58.
59. Summers RW, Elliott DE, Quadir K, et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003;98:2034-41.
60. Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 2004;53:620-2.
61. Sheil B, McCarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004;53:694-700.